Latest Insider Transactions at Kal Vista Pharmaceuticals, Inc. (KALV)
This section provides a real-time view of insider transactions for Kal Vista Pharmaceuticals, Inc. (KALV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of KalVista Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of KalVista Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
32,979
-8.19%
|
$494,685
$15.69 P/Share
|
|
Jul 09
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
30,250
-19.12%
|
$453,750
$15.69 P/Share
|
|
Jul 08
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+17.85%
|
-
|
|
Jul 08
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+27.5%
|
-
|
|
Jun 09
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,169
-2.22%
|
$100,366
$14.5 P/Share
|
|
Jun 06
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+4.62%
|
-
|
|
May 23
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,926
-1.92%
|
$21,186
$11.31 P/Share
|
|
May 23
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,146
-1.86%
|
$23,606
$11.31 P/Share
|
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.03%
|
-
|
|
May 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.16%
|
-
|
|
May 22
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,999
-3.16%
|
$109,989
$11.88 P/Share
|
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,317
-2.33%
|
$25,487
$11.88 P/Share
|
|
May 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,689
-2.38%
|
$29,579
$11.88 P/Share
|
|
May 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+6.84%
|
-
|
|
May 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+3.64%
|
-
|
|
May 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+5.25%
|
-
|
|
May 19
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,776
-2.54%
|
$30,536
$11.84 P/Share
|
|
May 19
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,808
-1.28%
|
$41,888
$11.84 P/Share
|
|
May 19
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,600
-2.65%
|
$28,600
$11.84 P/Share
|
|
May 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+5.57%
|
-
|
|
May 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,364
+3.05%
|
-
|
|
May 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+4.11%
|
-
|
|
Apr 09
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.47%
|
$225,000
$9.42 P/Share
|
|
Mar 07
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,669
-2.26%
|
$73,359
$11.97 P/Share
|
|
Mar 06
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+5.04%
|
-
|
|
Feb 24
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,918
-2.0%
|
$19,180
$10.02 P/Share
|
|
Feb 24
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,394
-2.27%
|
$23,940
$10.02 P/Share
|
|
Feb 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.16%
|
-
|
|
Feb 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.53%
|
-
|
|
Feb 18
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,104
-1.8%
|
$45,936
$9.82 P/Share
|
|
Feb 18
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,125
-3.02%
|
$28,125
$9.82 P/Share
|
|
Feb 18
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,601
-2.73%
|
$23,409
$9.82 P/Share
|
|
Feb 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,363
+3.19%
|
-
|
|
Feb 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+5.87%
|
-
|
|
Feb 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,204
+4.22%
|
-
|
|
Feb 13
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
61,700
+1.16%
|
$555,300
$9.33 P/Share
|
|
Feb 12
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.88%
|
$900,000
$9.23 P/Share
|
|
Feb 11
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
26,703
+0.52%
|
$240,327
$9.18 P/Share
|
|
Feb 10
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
4,137
+0.08%
|
$37,233
$9.14 P/Share
|
|
Feb 07
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
73,649
+1.43%
|
$662,841
$9.29 P/Share
|
|
Feb 03
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
14,562
+0.29%
|
$131,058
$9.22 P/Share
|
|
Jan 31
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
11,754
+0.23%
|
$94,032
$8.89 P/Share
|
|
Jan 30
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
43,707
+0.87%
|
$349,656
$8.76 P/Share
|
|
Dec 09
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,627
-2.7%
|
$68,643
$9.75 P/Share
|
|
Dec 06
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+5.25%
|
-
|
|
Nov 26
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,187
-2.2%
|
$19,683
$9.87 P/Share
|
|
Nov 26
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,963
-2.11%
|
$17,667
$9.87 P/Share
|
|
Nov 22
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.8%
|
-
|
|
Nov 22
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.25%
|
-
|
|
Nov 18
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,077
-7.9%
|
$72,693
$9.26 P/Share
|